OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Camidge on Targeted Therapies in Adjuvant NSCLC

May 7th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the selective administration of targeted therapies in the adjuvant setting for patients with non-small cell lung cancer.

Dr. von Minckwitz on Breast Cancer Responses

May 7th 2013

Gunter von Minckwitz, MD, PhD, discusses the current unsolved medical situation regarding patients with breast cancer who do not respond to treatment.

Dr. Vogelzang Discusses First-Line Axitinib in mRCC

May 6th 2013

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.

Dr. Advani Discusses Front-Line Brentuximab

May 6th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Dr. Petrylak Describes the Investigation of PROSTVAC

May 3rd 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes the clinical investigation of the immunotherapeutic vaccine PROSTVAC in men with castration-resistant prostate cancer.

Dr. Tripathy Reviews Targeted Therapies in Breast Cancer

May 3rd 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Dr. Tanyi Describes a Novel Two-Step Immunotherapy

May 2nd 2013

Janos L. Tanyi, MD, PhD, from the University of Pennsylvania, discusses two phase I studies that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Dr. Carey on the Future of Clinical Trial Design

May 2nd 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the present and future state of clinical trial design.

Dr. Melnick on the Epigenetic Basis of B-Cell Lymphomas

May 2nd 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses his presentation on the epigenetic basis of B-cell lymphomas at the 17th International Congress on Hematologic Malignancies.

Dr. Sandler on Orteronel in High-Risk Prostate Cancer

May 1st 2013

Howard M. Sandler, MD, from the Cedars-Sinai Medical Center, describes his excitement over research into new agents that modulate the androgen axis in prostate cancer.

Dr. Cheson on Targeting PD-1 in Hematologic Malignancies

May 1st 2013

Bruce D. Cheson, MD, from the Georgetown Lombardi Comprehensive Cancer Center, discusses the investigation of PD-1 targeted agents as treatments for patients with lymphoma.

Dr. Herbst on Selecting Patients for Molecular Testing

April 30th 2013

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, discusses determining the eligibility of patients with non-small cell lung cancer for molecular testing.

Dr. Esserman on Screening Patients With Higher-Risk DCIS

April 30th 2013

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, discusses screening patients with higher-risk DCIS.

Dr. Landgren on the Standard of Care in Multiple Myeloma

April 29th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with multiple myeloma.

Photos From the ONS 38th Annual Congress

April 29th 2013

Photos from the Oncology Nursing Society 38th Annual Congress, held at the Walter E. Washington Convention Center in Washington, D.C, from April 15-28, 2013.

Dr. Pegram on Combining Trastuzumab and Pertuzumab

April 26th 2013

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes the combination of pertuzumab and trastuzumab as a treatment for patients with HER2-positive metastatic breast cancer.

Dr. Crawford on the Prostate Cancer Treatment Landscape

April 25th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the rapidly changing treatment landscape for men with advanced prostate cancer.

Dr. Caudle on Upcoming Breast Cancer Trial Results

April 24th 2013

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Dr. Richard Silver Discusses the High Cost of Drugs in CML

April 24th 2013

Richard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.

Dr. Dreicer on Prostate Cancer Drug Development Challenges

April 23rd 2013

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses challenges facing the development of new lyase inhibitors and androgen receptor antagonists as treatments for men with prostate cancer.